SCHEMBL965024

SCHEMBL965024

C[C@@H](C(N)=O)c1ccc(NS(=O)(=O)c2ccccc2Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
PGR P06401 1/20 0.52
GAA P10253 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
MCL1 Q07820 1/20 0.46
SLC22A12 Q96S37 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31701338 0.90 PGR (0.53) ALDH1A1PGRGAAMEN1KMT2A
SCHEMBL1343769 0.88 ALDH1A1 (0.60) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL1346013 0.88 ALDH1A1 (0.60) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL965985 0.85 ATM (0.60) ALDH1A1PGRGAAMEN1KMT2A
SCHEMBL969745 0.81 ALDH1A1 (0.49) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL967450 0.81 MEN1 (0.56) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL27741918 0.81 MEN1 (0.56) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL965914 0.78 CES1 (0.61) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL8643785 0.78 CA12 (0.57) ALDH1A1GAAMEN1KMT2ALMNA
SCHEMBL28261322 0.76 HDAC3 (0.70) ALDH1A1HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024329-B1 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE SPA (IT) 2013-07-31 EP claimed
US-7868046-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them DOMPE' PHA.R.MA S.P.A. (IT) 2011-01-11 US claimed
US-20100152256-A1 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them DOMPE' PHA.R.MA S.P.A. (IT) 2010-06-17 US claimed
US-7652169-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them Dompe' Pha. R. Ma S.p.A. (IT) 2010-01-26 US claimed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US claimed
US-11932683-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets NEW YORK UNIVERSITY (US) 2024-03-19 US disclosed
US-20230151081-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS UNIV NEW YORK (US) 2023-05-18 US disclosed
US-11453715-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets NEW YORK UNIVERSITY (US) 2022-09-27 US disclosed
EP-3848046-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E New York University (US) 2021-07-14 EP disclosed
US-20210009664-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS UNIV NEW YORK (US) 2021-01-14 US disclosed
EP-3441474-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING A MUTATED LEUKOCIDIN E UNIV NEW YORK (US) 2020-07-22 EP disclosed
US-20190248876-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS UNIV NEW YORK (US) 2019-08-15 US disclosed
US-7652169-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them Dompe' Pha. R. Ma S.p.A. (IT) 2010-01-26 US disclosed
US-7652169-B2 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them Dompe' Pha. R. Ma S.p.A. (IT) 2010-01-26 US disclosed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them DOMPÉ FARMACEUTICI S.P.A. (IT) 2009-04-09 US disclosed
EP-2024329-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' pha.r.ma s.p.a. (IT) 2009-02-18 EP disclosed
WO-2007135080-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA. S.P.A. (IT) 2007-11-29 WO disclosed
WO-2007135080-A2 (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' PHA.R.MA. S.P.A. (IT) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11453715-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets CXCR1, CXCR2, CXCR5 ALDH1A1 3600/4885HDAC3 1963/4885HDAC4 3535/4885
US-20100152256-A1 (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them CCR2, CXCR2, CXCR4 ALDH1A1 2020/4885HDAC3 1365/4885HDAC4 2725/4885
US-20230151081-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS CXCR1, CXCR2, CXCR5 ALDH1A1 3600/4885HDAC3 1963/4885HDAC4 3535/4885
US-11932683-B2 Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets CXCR1, CXCR2, CXCR5 ALDH1A1 3600/4885HDAC3 1963/4885HDAC4 3535/4885
US-20090093530-A1 (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them CCR2, CXCR2, CXCR3 ALDH1A1 2130/4885HDAC3 1697/4885HDAC4 3339/4885
US-20190248876-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS CXCR1, CXCR2, CXCR5 ALDH1A1 3600/4885HDAC3 1963/4885HDAC4 3535/4885
US-20210009664-A1 CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS CXCR1, CXCR2, CXCR5 ALDH1A1 3600/4885HDAC3 1963/4885HDAC4 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.